Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables

Modern Rheumatology

Volumn 19, Issue 6, 2009, Pages 652-656

  Aramaki, Toshiyuki ^a   Kawakami, Atsushi ^a   Iwamoto, Naoki ^a   Fujikawa, Keita ^a   Kawashiri, Shin Ya ^a   Tamai, Mami ^a   Arima, Kazuhiko ^a   Kamachi, Makoto ^a   Yamasaki, Satoshi ^a   Nakamura, Hideki ^a   Nakashima, Munetoshi ^b   Mizokami, Akinari ^c   Furuyama, Masako ^d   Matsuoka, Naoki ^e   Ueki, Yukitaka ^f   Ida, Hiroaki ^a   Origuchi, Tomoki ^a   Aoyagi, Kiyoshi ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d Nagasaki Kita Hospital   (Japan)

^e Gotokai Hospital   (Japan)

^f SASEBO CHUO HOSPITAL   (Japan)

Author keywords

DAS; Gender; MTX; Rheumatoid arthritis; Tacrolimus

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28 C REACTIVE PROTEIN; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; REGRESSION ANALYSIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 73349121258     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0216-7     Document Type: Article

References (14)

1. PA Kelly GJ Burckart R Venkataramanan 1995 Tacrolimus: a new immunosuppressive agent Am J Health Syst Pharm 52 1569 1571
2. R Fleischmann I Iqbal RL Stern 2006 Tacrolimus in rheumatoid arthritis Expert Opin Pharmacother 7 91 98 10.1517/14656566.7.1.91 1:CAS:528: DC%2BD2MXhtlCmsrnF 16370926 (Pubitemid 43056425)
3. S Kawai K Yamamoto 2006 Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients Rheumatology 45 441 444 10.1093/rheumatology/kei172 1:CAS:528:DC%2BD28Xis1Gltr0%3D 16263777
4. S Kawai K Tanaka I Ohno K Utsunomiya Y Seino 2008 Safety of long-term therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients Mod Rheumatol 18 345 353 10.1007/s10165-008-0058-8 1:CAS:528:DC%2BD1cXpsVGnsbo%3D 18427723
5. K Akimoto Y Kusunoki S Nishio K Takagi S Kawai 2008 Safety profile of tacrolimus in patients with rheumatoid arthritis Clin Rheumatol 27 1393 1397 10.1007/s10067-008-0931-z 18506567
6. Y Morita Y Sasae T Sakuta M Satoh T Sasaki N Kashihara 2008 Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study Mod Rheumatol 18 379 384 10.1007/s10165-008- 0071-y 1:CAS:528:DC%2BD1cXpsVGnsbY%3D 18463945
7. JM Kremer JS Habros KS Kolba JL Kaine M Ann Borton LJ Mengle-Gaw, et al. 2003 Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate. A six-month, open-label study Arthritis Rheum 48 2763 2768 10.1002/art.11257 1:CAS:528:DC%2BD3sXpt1Sku7g%3D 14558080 (Pubitemid 37280603)
8. KG Saag GG Teng NM Patkar J Anuntiyo C Finney JR Curtis, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum (Arthritis Care & Research) 59 762 784 10.1002/art.23721 1:CAS:528:DC%2BD1cXot1Wgs74%3D (Pubitemid 351847559)
9. E Inoue H Yamanaka M Hara T Tomatsu N Kamatani 2007 Comparison of disease activity score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values Ann Rheum Dis 66 407 409 10.1136/ard.2006.054205 1:CAS:528:DC%2BD2sXjvFSht7o%3D 16926186 (Pubitemid 46579645)
10. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper, et al. 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 10.1002/art.1780310302 1:STN:280:DyaL1c7pt1Ohsg%3D%3D 3358796
11. SL Hilder AJ Silman W Thomson M Lunt D Bunn DP Symmons 2009 Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 68 57 62 10.1136/ard.2008.088237
12. D van der Heijde L Klareskog R Landewe GA Bruyn A Cantaqrel P Durez, et al. 2007 Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis Arthritis Rheum 56 3928 3939 10.1002/art.23141 18050208 (Pubitemid 350262318)
13. Y Tanaka T Takeuchi E Inoue K Saito N Sekiguchi E Sato, et al. 2008 Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) Mod Rheumatol 18 146 152 10.1007/s10165-008- 0026-3 1:CAS:528:DC%2BD1cXkt1Sksbo%3D 18283523
14. K Suzuki H Kameda K Amano H Nagasawa H Takei N Sekiguchi, et al. 2009 Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis Rheumatol Int 29 431 436 10.1007/s00296-008-0833-z 1:CAS:528:DC%2BD1MXhsFWnurw%3D 19127365